Annual Cash & Cash Equivalents:
$1.10B+$674.58M(+157.45%)Summary
- As of today, SRPT annual cash & cash equivalents is $1.10 billion, with the most recent change of +$674.58 million (+157.45%) on December 31, 2024.
- During the last 3 years, SRPT annual cash & cash equivalents has fallen by -$1.01 billion (-47.87%).
- SRPT annual cash & cash equivalents is now -47.87% below its all-time high of $2.12 billion, reached on December 31, 2021.
Performance
SRPT Cash and Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly Cash & Cash Equivalents:
$850.99M+$50.85M(+6.36%)Summary
- As of today, SRPT quarterly cash & cash equivalents is $850.99 million, with the most recent change of +$50.85 million (+6.36%) on September 30, 2025.
- Over the past year, SRPT quarterly cash & cash equivalents has dropped by -$347.40 million (-28.99%).
- SRPT quarterly cash & cash equivalents is now -60.80% below its all-time high of $2.17 billion, reached on March 31, 2020.
Performance
SRPT Quarterly Cash & Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SRPT Cash and Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1Y1 Year | +157.4% | -29.0% |
| 3Y3 Years | -47.9% | -58.9% |
| 5Y5 Years | +32.1% | -53.1% |
SRPT Cash and Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | |
|---|---|---|---|---|---|
| 3Y | 3-Year | -47.9% | +157.4% | -58.9% | +62.8% |
| 5Y | 5-Year | -47.9% | +157.4% | -59.8% | +62.8% |
| All-Time | All-Time | -47.9% | >+9999.0% | -60.8% | >+9999.0% |
SRPT Cash and Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2025 | - | $850.99M(+6.4%) |
| Jun 2025 | - | $800.14M(+53.1%) |
| Mar 2025 | - | $522.76M(-61.4%) |
| Dec 2024 | $1.10B(+157.5%) | $1.35B(+13.1%) |
| Sep 2024 | - | $1.20B(-17.9%) |
| Jun 2024 | - | $1.46B(+5.0%) |
| Mar 2024 | - | $1.39B(-17.0%) |
| Dec 2023 | $428.43M(-55.7%) | $1.68B(-3.3%) |
| Sep 2023 | - | $1.73B(-6.8%) |
| Jun 2023 | - | $1.86B(-1.1%) |
| Mar 2023 | - | $1.88B(-5.4%) |
| Dec 2022 | $966.78M(-54.3%) | $1.99B(-4.0%) |
| Sep 2022 | - | $2.07B(+7.5%) |
| Jun 2022 | - | $1.93B(-4.2%) |
| Mar 2022 | - | $2.01B(-4.8%) |
| Dec 2021 | $2.12B(+40.8%) | $2.12B(+32.3%) |
| Sep 2021 | - | $1.60B(-7.4%) |
| Jun 2021 | - | $1.73B(-0.6%) |
| Mar 2021 | - | $1.74B(-10.4%) |
| Dec 2020 | $1.50B(+79.9%) | $1.94B(+6.7%) |
| Sep 2020 | - | $1.82B(-11.9%) |
| Jun 2020 | - | $2.06B(-5.1%) |
| Mar 2020 | - | $2.17B(+93.0%) |
| Dec 2019 | $835.08M(+125.2%) | $1.12B(+7.2%) |
| Sep 2019 | - | $1.05B(-4.9%) |
| Jun 2019 | - | $1.10B(-17.9%) |
| Mar 2019 | - | $1.34B(+14.5%) |
| Dec 2018 | $370.83M(-38.2%) | $1.17B(+48.1%) |
| Sep 2018 | - | $792.86M(-16.5%) |
| Jun 2018 | - | $949.14M(-9.5%) |
| Mar 2018 | - | $1.05B(-2.8%) |
| Dec 2017 | $599.69M(+389.9%) | $1.08B(+74.7%) |
| Sep 2017 | - | $617.63M(+105.2%) |
| Jun 2017 | - | $300.95M(-22.9%) |
| Mar 2017 | - | $390.31M(+18.8%) |
| Dec 2016 | $122.42M(+52.4%) | $328.54M(-19.0%) |
| Sep 2016 | - | $405.83M(+203.1%) |
| Jun 2016 | - | $133.91M(-4.2%) |
| Mar 2016 | - | $139.85M(-31.2%) |
| Dec 2015 | $80.30M | $203.19M(+103.4%) |
| Sep 2015 | - | $99.91M(-36.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2015 | - | $156.89M(-5.6%) |
| Mar 2015 | - | $166.22M(-21.0%) |
| Dec 2014 | $73.55M(-71.4%) | $210.34M(-12.4%) |
| Sep 2014 | - | $240.02M(-15.3%) |
| Jun 2014 | - | $283.54M(+22.0%) |
| Mar 2014 | - | $232.44M(-12.0%) |
| Dec 2013 | $256.96M(+36.9%) | $264.21M(-5.9%) |
| Sep 2013 | - | $280.89M(+71.9%) |
| Jun 2013 | - | $163.44M(-2.7%) |
| Mar 2013 | - | $167.92M(-10.5%) |
| Dec 2012 | $187.66M(+370.3%) | $187.66M(+394.0%) |
| Sep 2012 | - | $37.99M(+55.1%) |
| Jun 2012 | - | $24.49M(-19.9%) |
| Mar 2012 | - | $30.57M(+14.8%) |
| Dec 2011 | $39.90M(+18.8%) | - |
| Dec 2010 | $33.59M(-30.4%) | - |
| Dec 2009 | $48.27M(+331.3%) | - |
| Dec 2008 | $11.19M(-54.9%) | - |
| Dec 2007 | $24.80M(+23.0%) | - |
| Dec 2006 | $20.16M(-41.7%) | - |
| Dec 2005 | $34.60M(+107.7%) | - |
| Dec 2004 | $16.65M(+33.0%) | - |
| Dec 2003 | $12.52M(+20.6%) | - |
| Dec 2002 | $10.38M(-6.2%) | - |
| Dec 2001 | $11.07M(-57.3%) | - |
| Mar 2001 | - | $26.62M(-30.2%) |
| Dec 2000 | $25.90M(+197.7%) | - |
| Sep 2000 | - | $38.15M(+260.8%) |
| Jun 2000 | - | $10.57M(+141.1%) |
| Dec 1999 | $8.70M(+2.4%) | - |
| Jun 1999 | - | $4.39M(-34.5%) |
| Mar 1999 | - | $6.69M(-38.8%) |
| Dec 1998 | $8.50M(-51.7%) | - |
| Sep 1998 | - | $10.93M(-17.2%) |
| Jun 1998 | - | $13.20M(-16.4%) |
| Mar 1998 | - | $15.79M(-10.3%) |
| Dec 1997 | $17.60M(+486.7%) | $17.60M(-4.9%) |
| Sep 1997 | - | $18.50M(+5.1%) |
| Jun 1997 | - | $17.60M(+665.2%) |
| Mar 1997 | - | $2.30M |
| Dec 1996 | $3.00M | - |
FAQ
- What is Sarepta Therapeutics, Inc. annual cash & cash equivalents?
- What is the all-time high annual cash & cash equivalents for Sarepta Therapeutics, Inc.?
- What is Sarepta Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
- What is Sarepta Therapeutics, Inc. quarterly cash & cash equivalents?
- What is the all-time high quarterly cash & cash equivalents for Sarepta Therapeutics, Inc.?
- What is Sarepta Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
What is Sarepta Therapeutics, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of SRPT is $1.10B
What is the all-time high annual cash & cash equivalents for Sarepta Therapeutics, Inc.?
Sarepta Therapeutics, Inc. all-time high annual cash & cash equivalents is $2.12B
What is Sarepta Therapeutics, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, SRPT annual cash & cash equivalents has changed by +$674.58M (+157.45%)
What is Sarepta Therapeutics, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of SRPT is $850.99M
What is the all-time high quarterly cash & cash equivalents for Sarepta Therapeutics, Inc.?
Sarepta Therapeutics, Inc. all-time high quarterly cash & cash equivalents is $2.17B
What is Sarepta Therapeutics, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, SRPT quarterly cash & cash equivalents has changed by -$347.40M (-28.99%)